SAN FRANCISCO and ILLKIRCH, France, April 6, 2011 /PRNewswire/
— Jennerex, Inc., a private clinical-stage biotherapeutics company
focused on the development and commercialization of first-in-class
targeted oncolytic products for cancer, and Transgene (NYSE
Euronext Paris: FR0005175080), a bio-pharmaceutical company
specialized in the development of immunotherapeutic products,
reported interim results from Phase 1 dose-escalation clinical
trials demonstrating that administration of JX-594 targets tumor
vasculature. By directly targeting and replicating within tumor
vasculature, JX-594 disrupts the blood supply to the solid tumors
contributing to destruction of the cancer. Data were reported in a
poster presentation at the 102nd Annual Meeting of the American
Association for Cancer Research (AACR) in Orlando, Florida.
“In addition to targeting, infecting and destroying cancer cells
and stimulating a targeted immune response against remaining cancer
cells, the analysis presented at AACR demonstrates JX-594’s
critical third mechanism of action—the disruption of the
blood supply to the tumor,” said David H. Kirn, M.D., president and
chief executive officer of Jennerex.
“Importantly, these data show that both intravenous and
intratumoral injection of JX-594 can effectively attack tumor
vasculature. These results further demonstrate that JX-594 may have
therapeutic benefit for a variety of solid tumors including liver,
colorectal and other cancers,” added Philippe Archinard, chairman
and chief executive officer of Transgene.
Twenty three patients were enrolled in the Phase 1
dose-escalation clinical study using intravenous JX-594 to treat
advanced, treatment refractory solid tumors. Tumor biopsies,
evaluated through immunohistochemical analysis, showed that JX-594
given intravenously infected the vasculature of tumors causing the
blood supply to the tumor to be disrupted. In addition, in another
trial of patients with primary liver can
‘/>”/>
